These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

615 related items for PubMed ID: 19643483

  • 1. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.
    McDonald MB, Protzko EE, Brunner LS, Morris TW, Haas W, Paterno MR, Comstock TL, Usner DW.
    Ophthalmology; 2009 Sep; 116(9):1615-1623.e1. PubMed ID: 19643483
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children.
    Silverstein BE, Allaire C, Bateman KM, Gearinger LS, Morris TW, Comstock TL.
    Clin Ther; 2011 Jan; 33(1):13-26. PubMed ID: 21397770
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Besifloxacin: a topical fluoroquinolone for the treatment of bacterial conjunctivitis.
    Chang MH, Fung HB.
    Clin Ther; 2010 Mar; 32(3):454-71. PubMed ID: 20399984
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis in adults and children.
    DeLeon J, Silverstein BE, Allaire C, Gearinger LS, Bateman KM, Morris TW, Comstock TL.
    Clin Drug Investig; 2012 May 01; 32(5):303-17. PubMed ID: 22420526
    [Abstract] [Full Text] [Related]

  • 9. Safety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and phase I safety studies.
    Comstock TL, Paterno MR, Decory HH, Usner DW.
    Clin Drug Investig; 2010 May 01; 30(10):675-85. PubMed ID: 20629472
    [Abstract] [Full Text] [Related]

  • 10. Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitis.
    Bertino JS, Zhang JZ.
    Expert Opin Pharmacother; 2009 Oct 01; 10(15):2545-54. PubMed ID: 19743941
    [Abstract] [Full Text] [Related]

  • 11. Clinical and Antibacterial Efficacy and Safety of Besifloxacin Ophthalmic Suspension Compared With Moxifloxacin Ophthalmic Solution.
    Garg P, Mathur U, Sony P, Tandon R, Morris TW, Comstock TL.
    Asia Pac J Ophthalmol (Phila); 2015 Oct 01; 4(3):140-5. PubMed ID: 26065499
    [Abstract] [Full Text] [Related]

  • 12. Besifloxacin ophthalmic suspension 0.6%.
    Carter NJ, Scott LJ.
    Drugs; 2010 Oct 01; 70(1):83-97. PubMed ID: 20030427
    [Abstract] [Full Text] [Related]

  • 13. The role of besifloxacin in the treatment of bacterial conjunctivitis.
    Mahvan TD, Hornecker JR, Buckley WA, Clark S.
    Ann Pharmacother; 2014 May 01; 48(5):616-25. PubMed ID: 24566460
    [Abstract] [Full Text] [Related]

  • 14. Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates.
    Sanfilippo CM, Allaire CM, DeCory HH.
    Drugs R D; 2017 Mar 01; 17(1):167-175. PubMed ID: 28078599
    [Abstract] [Full Text] [Related]

  • 15. The safety of besifloxacin ophthalmic suspension 0.6 % used three times daily for 7 days in the treatment of bacterial conjunctivitis.
    Malhotra R, Ackerman S, Gearinger LS, Morris TW, Allaire C.
    Drugs R D; 2013 Dec 01; 13(4):243-52. PubMed ID: 24142473
    [Abstract] [Full Text] [Related]

  • 16. Topical ophthalmic moxifloxacin elicits minimal or no selection of fluoroquinolone resistance among bacteria isolated from the skin, nose, and throat.
    Lichtenstein SJ, De Leon L, Heller W, Marshall B, Cupp G, Foster K, McLean C, Levy S, Stroman DW.
    J Pediatr Ophthalmol Strabismus; 2012 Dec 01; 49(2):88-97. PubMed ID: 22074357
    [Abstract] [Full Text] [Related]

  • 17. Clinical cure of bacterial conjunctivitis with azithromycin 1%: vehicle-controlled, double-masked clinical trial.
    Abelson MB, Heller W, Shapiro AM, Si E, Hsu P, Bowman LM, AzaSite Clinical Study Group.
    Am J Ophthalmol; 2008 Jun 01; 145(6):959-65. PubMed ID: 18374301
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and Safety of 0.6% Pazufloxacin Ophthalmic Solution Versus Moxifloxacin 0.5% and Gatifloxacin 0.5% in Subjects with Bacterial Conjunctivitis: A Randomized Clinical Trial.
    Baiza-Durán L, Olvera-Montaño O, Mercado-Sesma AR, Oregon-Miranda AA, Lizárraga-Corona A, Ochoa-Tabares JC, Pérez-Balbuena AL, Montoya-Sánchez IM, Saucedo-Rodríguez LR, Mora-González A, Gómez-Bastar PA, Villanueva-Najera MA, Sandoval-Delgadillo LI, González-Lomelí M, Páez-Garza JH, Orozco-Carroll M, Casillas-Magallanes M.
    J Ocul Pharmacol Ther; 2018 Apr 01; 34(3):250-255. PubMed ID: 29624493
    [Abstract] [Full Text] [Related]

  • 19. Clinical safety of moxifloxacin ophthalmic solution 0.5% (VIGAMOX) in pediatric and nonpediatric patients with bacterial conjunctivitis.
    Silver LH, Woodside AM, Montgomery DB.
    Surv Ophthalmol; 2005 Nov 01; 50 Suppl 1():S55-63. PubMed ID: 16257311
    [Abstract] [Full Text] [Related]

  • 20. A phase III clinical trial of 0.5% levofloxacin ophthalmic solution versus 0.3% ofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis.
    Schwab IR, Friedlaender M, McCulley J, Lichtenstein SJ, Moran CT, Levofloxacin Bacterial Conjunctivitis Active Control Study Group.
    Ophthalmology; 2003 Mar 01; 110(3):457-65. PubMed ID: 12623805
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.